Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
Find out more about us
28 July 2022
04 July 2022
26 April 2022
Find out more
TYK2/JAK1 inhibitor SDC-1801, targeting autoimmune diseases, is being prepared for first clinical studies in 2022
Sareum has an innovative pipeline of drug development candidates.
IMC SDC-1801 CTA submission, Aug 2022BioTrinity, April 2022 IMC Half Year Results, Feb 2022IMC Full Year Results, Oct 2021
Share price dataRegulatory News Service (RNS)
Sareum LimitedUnit 2A, Langford ArchLondon Road, PampisfordCambridge CB22 3FXUnited Kingdom
tel: +44 (0) 1223 497700fax: +44 (0) 1223 497701
Full-year Results 2021 ¦
Annual Report 2021 ¦